36C24E26Q0016.docx
DOCX document 30 KB Posted
- Attached to
- AN11--Research Lab Services - Blood Serum Assay Testing of Buprenorphine and Norbuprenorphine Levels
- Solicitation number
- 36C24E26Q0016
About this file
This is a Sources Sought Notice issued by the Department of Veterans Affairs (VA) Veterans Health Administration Regional Procurement Office East for research laboratory services. The notice seeks information from qualified vendors regarding blood serum assay testing capabilities for buprenorphine and norbuprenorphine levels to support CSP #2014, a comparative effectiveness study (VA-BRAVE) evaluating two formulations of buprenorphine for treating opioid use disorder in veterans across 20 VA sites. The study requires testing of approximately 498 participants three times across three years, totaling approximately 1,494 assessments. The solicitation number is 36C24E26Q0016, and responses are due by February 24, 2026 at 3:00 PM Eastern Time. The place of performance is the vendor's site, with results delivered to Boston VA Healthcare System Research Services at 150 South Huntington Avenue, Boston, MA 02130.
Vendors must provide capability statements demonstrating CLIA certification, previous experience with the requested services, and clear understanding of subcontractor networks if applicable. Required deliverables include blood toxicology sample collection, shipping supplies (screening devices, vacutainer tubes, requisition forms, specimen baggies, and overnight FedEx shipping), and a web-based secure portal for specimen collection and reporting with search, management, and printing capabilities, data export functionality, and real-time tracking from collection through results. Laboratory analysis must be performed using GC-MS or LC-MS/MS methodology. Responses should include company SAM.gov Unique Entity ID number and business status (large, small, VOSB, or SDVOSB). This is market research only; responses will not be returned and no debriefs will be conducted. The contracting officer is Ann Marie Stewart, contact information annmarie.stewart@va.gov.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sources Sought Notice Sources Sought Notice
| SUBJECT* |
| Research Lab Services - Blood Serum Assay Testing of Buprenorphine and Norbuprenorphine Levels |
GENERAL INFORMATION
| CONTRACTING OFFICE’S ZIP CODE* |
| 15215-1802 |
| SOLICITATION NUMBER* |
| 36C24E26Q0016 |
| RESPONSE DATE/TIME/ZONE |
| 02-24-2026 15:00 EASTERN TIME, NEW YORK, USA |
| ARCHIVE |
| 90 DAYS AFTER THE RESPONSE DATE |
| RECOVERY ACT FUNDS |
| N |
SET-ASIDE
| PRODUCT SERVICE CODE* |
| AN11 |
| NAICS CODE* |
| 621511 |
| CONTRACTING OFFICE ADDRESS |
| Veterans Health Administration |
Regional Procurement Office East Building 32 Suite 1A1111 1010 Delafield Road Pittsburgh PA 15215-1802
POINT OF CONTACT*
Contracting Officer Ann Marie Stewart annmarie.stewart@va.gov 401-919-0878
PLACE OF PERFORMANCE
| ADDRESS |
| Selected Vendor for |
Boston VA Healthcare System
Research Services
150 South Huntington Avenue
Boston MA
| POSTAL CODE |
| 02130 |
| COUNTRY |
| USA |
ADDITIONAL INFORMATION
DESCRIPTION
SOURCES SOUGHT NOTICE
Sources Sought: This is NOT a solicitation for a proposal, proposal abstract, or quote. The purpose of this notice is to obtain information regarding qualified business sources. The responses to the information requested will assist the Government in determining the appropriate acquisition method.
STATEMENT OF WORK
Contract Title: Blood Serum Assay Testing of Buprenorphine and Norbuprenorphine Levels Background: CSP #2014 Comparative Effectiveness of Two Formulations of Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE) is a comparative effectiveness study evaluating formulations of buprenorphine in Veterans with opioid use disorder (OUD) across 20 VA sites in the US. This is the first study of its kind in the VA and the first study comparing these two formulations in a “real world” clinical population. The study is comparing the Food and Drug Administration (FDA)-approved long acting injectable (LAI, (monthly)) buprenorphine (Sublocade), with the current standard of care, sublingual (SL) daily buprenorphine plus naloxone film.
Scope: This study requires blood buprenorphine and norbuprenorphine testing on approximately four hundred ninety-eight (498 participants three (3) times across three (3) years totaling approximately one thousand four hundred ninety-four (1,494) assessments.
Specific Tasks & Deliverables:
1. TASK: Collection of blood toxicology samples
2. TASK: Shipping supplies for blood toxicology samples to include:
a. Substance abuse screening device
b. Vacutainer Grey Top Tubes 10 mL
c. Test Requisition Forms (2 part, pre-printed)
d. Large Zip Locks (to go inside FedEx pack)
e. 2 Pouch Specimen baggies (for each case)
f. FedEx overnight shipping Pak/Box with preprinted label to laboratory
Requirements Result Reporting: Web-based specimen collection and reporting tool (with search, management, printing capabilities) via a secure web portal for CSP personnel to be able to access and export data is required. Results will be made available and maintained by the vendor. Data shall be input and uploaded to the designated vendor web portal and reports will be made available according to the requisition form immediately following test results. Data to be provided (at a minimum): specimen ID (study ID), date blood received, date tested, and result (see output analysis section). The web portal shall be able to export the data; only showing the data without the ability to download is not acceptable. It must provide the ability to locate, view, print and save participant de-identified results. It must allow access to monthly reports, drug statistics, participant summaries, and for real-time tracking from collection through to the report.
Output Analysis: Blood Toxicology Screens (determination and concentration of drug and/or metabolite) by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography – tandem mass spectrometry (LC-MS/MS) of:
· Buprenorphine
· Norbuprenorphine
*** Lab must be CLIA (Clinical Laboratory Improvement Amendments) Certified
Period of Performance: Base plus 2 option years
Place of Performance: Vendor Site
SUMMARY:
This is a Sources Sought notice and not a request for quotes. This request is solely for the purpose of conducting market research to enhance the contracting officer’s understanding of the market’s offered products, services, and capabilities. The Government will not pay any costs for responses submitted in response to this Sources Sought.
This Sources Sought notice provides an opportunity for respondents to submit their notice of ability, and their available products and services in response to the requirement. Vendors are invited to submit information relative to their potential of fulfilling this requirement in the form of a capability response that addresses the specific requirement identified in this Sources Sought.
This Sources Sought is to facilitate the Contracting Officer’s review of the market base, for acquisition planning, size determination, and procurement strategy.
RESPONSE
A. Please provide a capability statement with general understanding of the industry with current knowledge and subcontract networks that would be used to support the requirement as identified herein. Information should suggest, NACIS Code, provide the socioeconomic status for your company and your subcontractors if you are planning on supporting this service with subcontractors. The limitations of subcontracting applies. The primary contractor must hold the required CLIA certification. The primary Contractor must perform more than the management and administrative functions on this requirement, and the primary Contractor must have previous experience in the services requested.
Submittals furnished will not be returned to the sender. No debriefs will be conducted. Eligibility in participating in a future acquisition does not depend upon a response to this notice.
1. The capability statement must show clear detailed qualifications that will meet this requirement.
2. Please provide your company’s business status and any subcontractor’s business status: Large, Small, VOSB, or an SDVOSB.
3. Please include your company’s SAM.gov Unique Entity ID (UEI) number. All companies doing business with the Government must be registered in SAM.gov under “All Awards” at time of solicitation and at time of award.
B. Proprietary information is neither requested nor desired. If such information is submitted, it must clearly be marked "proprietary" on every sheet containing such information, and the proprietary information must be segregated to the maximum extent practicable from other portions of the response (e.g., use an attachment or exhibit).
C. Submit responses by email only to annmarie.stewart@va.gov
Timeline: This request will close on 02/24/2026 at 3 PM EST.
The Department of Veteran Affairs Contracting Office POC:
Ann Marie Stewart Contracting Officer annmarie.stewart@va.gov
Sources Sought Notice
Sources Sought Notice
File details come from the government source that posted it. Updated .